Literature DB >> 11976442

Schizophrenia: diverse approaches to a complex disease.

Akira Sawa1, Solomon H Snyder.   

Abstract

Schizophrenia is a debilitating mental illness that affects 1% of the population. Despite intensive study, its molecular etiology remains enigmatic. Like many common diseases, schizophrenia is multifactorial in origin, with both genetic and environmental contributions likely playing an important role in the manifestation of symptoms. Recent advances based on pharmacological studies, brain imaging analyses, and genetic research are now converging on tantalizing leads that point to a central role for several neurotransmitters, including dopamine, glutamate, and serotonin, that may interface with neurodevelopmental defects reflecting disease-related genetic aberrations. Here, we provide a brief overview of the parallel approaches being used to identify the molecular causes of schizophrenia and discuss possible directions for future research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976442     DOI: 10.1126/science.1070532

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  119 in total

1.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

2.  Elucidating the pathogenesis of schizophrenia.

Authors:  Akira Sawa; Atsushi Kamiya
Journal:  BMJ       Date:  2003-09-20

3.  Neurosurgical interventions for neuropsychiatric syndromes.

Authors:  C Alan Anderson; David B Arciniegas
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

4.  Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.

Authors:  Daniel K Putnam; Jingchun Sun; Zhongming Zhao
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

Review 5.  The neuropsychology of self-reflection in psychiatric illness.

Authors:  Carissa L Philippi; Michael Koenigs
Journal:  J Psychiatr Res       Date:  2014-03-18       Impact factor: 4.791

6.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

7.  Proline-directed phosphorylation of the dopamine transporter N-terminal domain.

Authors:  Balachandra K Gorentla; Amy E Moritz; James D Foster; Roxanne A Vaughan
Journal:  Biochemistry       Date:  2009-02-10       Impact factor: 3.162

Review 8.  Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.

Authors:  Hanna Jaaro-Peled; Yavuz Ayhan; Mikhail V Pletnikov; Akira Sawa
Journal:  Schizophr Bull       Date:  2009-11-10       Impact factor: 9.306

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

10.  Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.

Authors:  José L Moreno; Terrell Holloway; Adrienne Umali; Vinayak Rayannavar; Stuart C Sealfon; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2012-07-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.